Results 81 to 90 of about 96,798 (264)
, 2011 The implantable cardioverter defibrillator (ICD) is the gold standard therapy to prevent life-threatening arrhythmias. Phobic anxiety predicts ventricular arrhythmia in coronary heart disease patients, but little is known about phobic anxiety in ICD ...
Cho, En-Young Nicole +16 more
core +1 more source
In vivo mechanical loading conditions of pectorally implanted cardiac pacemakers : feasibility of a force measurement system and concept of an animal-human transfer function [PDF]
, 2009 Includes abstract.Includes bibliographical references (leaves 92-98).The objectives of this study were to assess the feasibility of this system for measuring in vivo mechanical loading on pectorally implanted pacemakers, to compare differences in ...
De Vaal, Michael Hamman
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1227-1236, April 2025.Comparative performance of 7 risk prediction indices in patients hospitalized for heart failure. In this cohort of 1206 patients, the LENT index offered the greatest discrimination, calibration, and overall accuracy in predicting 30‐day composite all‐cause mortality or readmission following hospitalization for heart failure.
Tauben Averbuch +8 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul +13 more
wiley +1 more source
International Journal of Cardiology: Heart & Vasculature, 2019 Backgrounds: Some patients who undergo implantation of cardiac resynchronization therapy with defibrillator (CRT-D) survive long enough, thus requiring CRT-D battery replacement.
Michio Ogano +7 more
doaj +1 more source
Considerations for drug trials in hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source
Impact of the implantable cardioverter-defibrillator on rehospitalizations
, 1996 Patients who survive out-of-hospital ventricular tachycardia or ventricular fibrillation are at risk of sudden cardiac death and often return to hospital after initial discharge.
A. Fischer +9 more
core +1 more source
A Woman with Electrocardiographic ST-segment Elevation After a Road Traffic Accident
Indian Journal of Clinical CardiologyWe present the case of a woman in her mid-50s with suspected arrhythmic syncope while she was driving owing to fever-induced Brugada syndrome. The patient was appropriately managed with prompt antipyretic treatment and an implantable cardioverter ...
Andreas Y. Andreou +2 more
doaj +1 more source
Indian Pacing and Electrophysiology Journal, 2019 Dextrocardia is a congenital anomaly where the heart is abnormally located in the right hemithorax. In these patients, the implementation of transvenous implantable cardioverter-defibrillator (TV-ICD) can be technically challenging and pose a higher risk
Ariel González-Cordero +2 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh +18 more
wiley +1 more source